MEDAREX, INC. AND GENPAT77 ANNOUNCE THERAPEUTIC ANTIBODY CO-DEVELOPMENT AGREEMENT

Medarex, Inc. and GenPat77 Pharmacogenetics AG, a privately held biopharmaceutical company focused on the development of immune modulatory products, have entered into a collaborative agreement to develop fully human therapeutic antibody products. The companies plan to use Medarex's UltiMAb Human Antibody Development System to generate antibodies to novel disease targets provided by GenPat77.

BioSpace (http://www.biospace.com/news_story.aspx?StoryID=28038&full=1)